Company / Cash & Equivalents
NeuroPace Inc Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$21.7M
FY2025
5-year range
$6.6M / $21.7M
FY2021-FY2025
Trend
+61.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 5 years, ranging from $7M in FY2022 to $22M in FY2025.
Based on SEC 10-K filings.
$22M in FY2025 with a 3-year CAGR of +48.6%.
Improved from $18M to $22M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +48.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +48.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 61.5% year-over-year.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $21.7M | +61.5% |
| FY2024 | $13.4M | -25.6% |
| FY2023 | $18.1M | +173.4% |
| FY2022 | $6.6M | -65.6% |
| FY2021 | $19.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026